Title |
Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer
|
---|---|
Published in |
Oncotarget, January 2016
|
DOI | 10.18632/oncotarget.6871 |
Pubmed ID | |
Authors |
Qian Zhao, Zhongtang Wang, Wei Huang, Qiang Wang, Shuzeng Yu, Tao Zhou, Dan Han, Zhenying Wu, Heyi Gong, Hongfu Sun, Jian Zhang, Yumei Wei, Hongsheng Li, Zicheng Zhang, Haiqun Lin, Baosheng Li |
Abstract |
Our aim was to evaluate the efficacy and safety of cisplatin with pemtrexed or vinorelbine and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT). Patients with unresectable stage III non-small-cell lung cancer (NSCLC) were randomly assigned to two regimens. The experimental (PP) arm included cisplatin, pemtrexed and concurrent LCAHRT based on bilateral lung V20 = 33%. The control (NP) arm used cisplatin, vinorelbine with the same radiotherapy protocol. The primary endpoint was overall survival. Median survival times were 26.0 months (95% CI 23.2 to 28.7 months) and 28.5 months (95% CI 17.1 to 39.9 months) for the NP and PP arms, respectively (P = 0.26). Median progression-free survival was 12.5 months and 17.5 months in the NP and PP arms (P = 0.07). In both arms of the study, there were no differences in overall survival between patients with squamous and nonsquamous NSCLC. The incidences of grade 3 or 4 toxicity were higher in NP than PP arm. With concurrent LCAHRT, pemetrexed/cisplatin was equally as efficacious as vinorelbine/cisplatin, but showed a more favorable toxicity profile. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 22% |
Student > Bachelor | 5 | 14% |
Student > Master | 4 | 11% |
Other | 3 | 8% |
Professor | 3 | 8% |
Other | 9 | 24% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 30% |
Nursing and Health Professions | 7 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Agricultural and Biological Sciences | 2 | 5% |
Social Sciences | 2 | 5% |
Other | 7 | 19% |
Unknown | 6 | 16% |